Revvity Inc (RVTY)

Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell

$89.22

Buy

$91.79

arrow-down$-0.20 (-0.22%)

PerkinElmer Inc is a diagnostics company that provides instruments, consumables, and services to biomedical, chemical and to general industrial markets. It operates in two segments namely Discovery and Analytical Solutions and Diagnostics.
Prices updated at 30 May 2025, 21:44 EDT
| Prices minimum 15 mins delay
|
Prices in USD
S&P 500
arrow-down-0.01%
NYSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Diagnostics & Research
Chairman
Mr. Alexis P. Michas
CEO
Dr. Prahlad R. Singh, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
11,000
Head office
77 4th Avenue
Waltham
United States
02451
mobile
+1 781 663-6900
letter
-
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Alexis P. Michas
Non-Executive Chairman of the Board
0.18m--0.45m-
Mr. Joel S. Goldberg
Senior Vice President, Administration, General Counsel and Secretary
0.55m--3.38m-
Dr. Peter Barrett,PhD
Independent Director
0.11m--0.33m-
Mr. Tajinder Vohra
Senior Vice President, Global Operations
0.48m--2.31m-
Dr. Sophie V. Vandebroek, PhD
Independent Director
0.08m--0.36m-
Dr. Frank R. Witney,, PhD
Independent Director
0.09m--0.32m-
Ms. Pascale Witz, M. Sc.,M.B.A.
Independent Director
0.09m--0.31m-
Mr. Michel Vounatsos
Independent Director
0.11m--0.33m-
Dr. Prahlad R. Singh, PhD
Director, President and Chief Executive Officer
1.10m--11.93m-
Mr. Samuel R. Chapin
Independent Director
0.12m--0.34m-
Ms. Miriame Victor
Senior Vice President and Chief Commercial Officer
0.47m--2.48m-
Mr. Michael A Klobuchar
Independent Director
0.08m--0.36m-
Dr. Michelle McMurry-Heath, PhD
Independent Director
0.09m--0.31m-
Mr. Maxwell Krakowiak
Senior Vice President and Chief Financial Officer
0.51m--3.25m-
Ms. Anita Gonzales
Vice President and Controller
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
T. Rowe Price Investment Management,Inc.22,515,7111.5758417544038.45034930 Apr 202518.86
Vanguard Group Inc14,382,8490.02751926380.64826230 Apr 202512.05
T. Rowe Price Capital Appreciation Fund14,181,0642.343078657416.5018430 Apr 202511.88
T. Rowe Price Associates, Inc.9,563,9110.12467193231425.31991730 Apr 20258.01
Janus Capital Management LLC8,968,3744.46446-471779-30 Apr 20257.51

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
16 Dec 2024-Ms. Anita Gonzales115.942,8993,992--
02 Dec 2024-Dr. Prahlad R. Singh, PhD81.291,492,891108,560--
02 Dec 2024-Dr. Prahlad R. Singh, PhD-----
02 Dec 2024-Dr. Prahlad R. Singh, PhD116.63382,19790,195--
02 Dec 2024-Dr. Prahlad R. Singh, PhD116.131,752,16993,472--
09 Oct 2024-Mr. Tajinder Vohra122.562,45119,652--
09 Oct 2024-Mr. Tajinder Vohra121.72259,75019,672--
07 Oct 2024-Mr. Tajinder Vohra122.04250,54824,060--
08 Oct 2024-Mr. Tajinder Vohra122.9960,63421,806--
08 Oct 2024-Mr. Tajinder Vohra122.47203,42322,299--
07 Oct 2024-Mr. Tajinder Vohra123.0512,30523,960--
16 Sep 2024-Ms. Anita Gonzales122.0318,1824,017--
15 Aug 2024-Mr. Alexis P. Michas118.62100,8277,770--
07 Aug 2024-Mr. Joel S. Goldberg116.06111,88235,936--
07 Aug 2024-Mr. Joel S. Goldberg119.48125,21533,400--
07 Aug 2024-Mr. Joel S. Goldberg118.8093,25834,448--
07 Aug 2024-Mr. Joel S. Goldberg116.8682,15335,233--
17 Jun 2024-Ms. Anita Gonzales108.653,4774,166--
07 Jun 2024-Mr. Joel S. Goldberg110.32311,54438,076--
07 Jun 2024-Mr. Joel S. Goldberg110.80130,30136,900--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.